Ultra Market Research | United States (US) non small cell lung cancer (NSCLC) market
United States (US) non small cell lung cancer (NSCLC) market
Report ID : 918
Category : United-States(US)
No Of Pages : 100
Published on: January 2025
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
United States (US) non small cell lung cancer (NSCLC) market
Introduction The US non-small cell lung cancer market is a vital area of focus within the oncology industry. Focused on one of the most common forms of lung cancer, NSCLC accounts for roughly 85% of all cases of lung cancer. There are three types: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Innovation-based therapies like immunotherapies and targeted treatments drive this market and transform patient outcomes. Recent trends include advances in precision medicine, biomarker-based therapies, and a trend toward personalized treatment regimens. The market is valued at approximately $9.5 billion as of 2023 and is expected to grow at a very high CAGR due to rising disease prevalence and R&D. Challenges such as high treatment costs and access disparities persist, thus forming the dynamic landscape of the market.
Market Segmentation Therapy Type
• Targeted Therapy o EGFR Inhibitors Osimertinib Erlotinib Others o ALK Inhibitors Crizotinib Alectinib o Others • Immunotherapy o PD-1/PD-L1 Inhibitors Pembrolizumab Nivolumab o CTLA-4 Inhibitors Ipilimumab o Others • Chemotherapy o Platinum-Based Agents Cisplatin Carboplatin o Taxanes Paclitaxel Docetaxel o Others
Stage • Early Stage (Stage I-II) o Surgical Interventions Lobectomy Pneumonectomy Others o Adjuvant Therapy Radiotherapy Chemotherapy • Advanced Stage (Stage III-IV) o Systemic Therapies Targeted Therapy Immunotherapy o Palliative Care Pain Management Supportive Therapy
Biomarker Status • EGFR Mutant o EGFR T790M Mutation o Exon 19 Deletion • ALK Positive o ROS1 Rearrangement o Others • PD-L1 Positive o High Expression (>50%) o Low Expression (<50%)
List of Market Players 1. AstraZeneca (United Kingdom) 2. Bristol-Myers Squibb (United States) 3. Merck & Co. (United States) 4. Roche (Switzerland) 5. Pfizer Inc. (United States) 6. Novartis (Switzerland) 7. Eli Lilly and Company (United States) 8. Amgen (United States) 9. Sanofi (France) 10. Takeda Pharmaceutical (Japan) 11. Boehringer Ingelheim (Germany) 12. GlaxoSmithKline (United Kingdom) 13. Johnson & Johnson (United States) 14. AbbVie (United States) 15. Bayer AG (Germany)
Drivers Drivers for the US non-small cell lung cancer (NSCLC) market include rising incidence of lung cancer, due to smoking, pollution, and genetic predispositions. The increase in demand for effective therapies is expected. Advances in molecular diagnostics and identification of biomarkers have paved the way for precision medicine. Precision medicine, ensuring targeted therapies are more effective, has emerged with innovations in immunotherapy, such as checkpoint inhibitors like pembrolizumab and nivolumab, which show survival benefits. Government initiatives and increased healthcare expenditure further support market growth. The growing elderly population, a primary demographic for lung cancer, also contributes to market expansion. Pharmaceutical companies' heavy investment in R&D for next-generation treatments, coupled with expedited regulatory approvals, underscores the market's positive trajectory.
Restraints With high level of advancement still, the NSCLC in the US continues to face big challenges. Mainly, because of the therapy cost, in particular immunotherapies and target therapies, to reach the uninsured patients or those covered by underinsurance, it does create issues. Reimbursement also imposes a constraint here. The tumor's genetic aspect is complex which makes the developing process of its treatment time and cost-intensive. Side effects as well, specifically immune-related side effects from the checkpoint inhibitors could be a turnoff for widespread adaptation. Regulatory barriers, mainly due to new drugs and new combinations, increase the timeline for entering the market. In addition, health care gaps exist between rural and inner-city populations, which further complicate the equal dispensation of treatment. This concentration affects market expansion.
Opportunities Huge opportunities for growth remain in the market for NSCLC in the US. New therapies biomarker-driven will take the treatment of NSCLC to the next level, allowing for better efficacy and fewer side effects. NGS technologies help sequence genes fast and detect actionable mutations that have increased the scope of drugs targeted in NSCLC therapy. Increased partnership between biotech firms and academia also supports innovation and pipeline development. There are also huge additional revenue streams in expanding indications for existing immunotherapies, such as checkpoint inhibitors. Much promise lies in combination therapies, pairing immunotherapy with chemotherapy or targeted agents, to enhance outcomes even more. Continued digitalization of healthcare through AI-driven diagnostic tools promises optimization of treatment planning and patient monitoring.
Trends Some of the key trends in the US non-small cell lung cancer (NSCLC) market are a shift toward precision oncology and real-world evidence-based approaches. Liquid biopsies are gaining popularity for non-invasive monitoring of disease progression and treatment response. AI and machine learning are enhancing drug discovery and patient stratification. Combination therapies are increasingly being tested in clinical trials, with an aim to improve overall survival rates. Telemedicine expansion also has provided more effective management of patients, especially for patients in rural and remote settings. Increased attention on patient-centered care, incorporating psychosocial care into the overall treatment approach, is evidence of a multidimensional approach to the management of cancer.
8.1.10 Johnson & Johnson (United States)• Business Overview• Product Portfolio• Strategic Developments• Financial Overview
9. Conclusion and Recommendations
10. List of Tables and figures
• Table 1: United States NSCLC Market Size by Therapy Type (2024-2030)
• Table 2: United States NSCLC Market Size by Stage (2024-2030)
• Table 3: United States NSCLC Market Size by Biomarker Status (2024-2030)
• Table 4: United States NSCLC Market Size by Distribution Channel (2024-2030)
• Table 5: Financial Overview of Key Companies
• Figure 1: United States NSCLC Market Growth Rate by Therapy Type (2024-2030)
• Figure 2: United States NSCLC Market Growth Rate by Stage (2024-2030)
• Figure 3: United States NSCLC Market Growth Rate by Biomarker Status (2024-2030)
• Figure 4: United States NSCLC Market Growth Rate by Distribution Channel (2024-2030)
• Figure 5: Market Share Analysis of Key Companies (2024)
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of United States (US) non small cell lung cancer (NSCLC) market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of United States (US) non small cell lung cancer (NSCLC) Market for the past year and forecasts for the next six years. United States (US) non small cell lung cancer (NSCLC) market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different United States (US) non small cell lung cancer (NSCLC) market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for United States (US) non small cell lung cancer (NSCLC) market from different application industries in different regions.
Segmentation By Therapy Type • Targeted Therapy o EGFR Inhibitors Osimertinib Erlotinib Others o ALK Inhibitors Crizotinib Alectinib o Others • Immunotherapy o PD-1/PD-L1 Inhibitors Pembrolizumab Nivolumab o CTLA-4 Inhibitors Ipilimumab o Others • Chemotherapy o Platinum-Based Agents Cisplatin Carboplatin o Taxanes Paclitaxel Docetaxel o Others
By Stage • Early Stage (Stage I-II) o Surgical Interventions Lobectomy Pneumonectomy Others o Adjuvant Therapy Radiotherapy Chemotherapy • Advanced Stage (Stage III-IV) o Systemic Therapies Targeted Therapy Immunotherapy o Palliative Care Pain Management Supportive Therapy
By Biomarker Status • EGFR Mutant o EGFR T790M Mutation o Exon 19 Deletion • ALK Positive o ROS1 Rearrangement o Others • PD-L1 Positive o High Expression (>50%) o Low Expression (<50%)
By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Specialty Pharmacies • Online Pharmacies
